多功能双特异性纳米纤维向SLAMF7触发力强抗瘤免疫力
Manman Zhu1, Yongjian Wu1, Tianchuan Zhu1
1Center for Infection and Immunity and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
Cancer immunology research
|May 31, 2024
概括
针对SLAMF7和GPC3的新型纳米纤维增强了肝细胞癌 (HCC) 的抗瘤免疫力. 这种方法克服了TME抑制并使瘤对PD1阻塞敏感,提供了一种新的癌症治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 纳米技术 纳米技术
- 在瘤学瘤学.
背景情况:
- 免疫检查点抑制剂 (ICI) 治疗的有效性受到细胞毒性T细胞透不良和免疫抑制性瘤微环境 (TME) 的限制.
- 信号淋巴细胞激活分子家族成员7 (SLAMF7) 是一种协同刺激的受体,可以激活NK细胞,T细胞和巨细胞对抗瘤.
- 在固体瘤中SLAMF7的治疗潜力仅限于它仅在造血细胞上表达.
研究的目的:
- 开发和描述针对SLAMF7和glypican-3 (GPC3),肝细胞癌 (HCC) 特定抗原的多功能双特异性纳米纤维 (NVs).
- 调查这些NVs诱导抗瘤免疫力和重塑TME的能力.
主要方法:
- 开发针对SLAMF7和GPC3.3设计的双特异性纳米纤维 (NVs).
- 描述NV向效率及其对瘤微环境的影响.
- 评估NV诱导的抗瘤免疫力和与PD1阻断的协同作用.
主要成果:
- 开发的NV有效地通过准SLAMF7和GPC3.3来装饰固体瘤表面.
- 用NVs准SLAMF7诱导了强有力的和特定的抗瘤免疫反应.
- 这些NV重塑了免疫抑制的TME,并使瘤对编程细胞死亡蛋白1 (PD1) 阻塞敏感.
结论:
- 针对SLAMF7的多功能双特异性NVs是增强抗瘤免疫力的有希望的策略.
- 这种方法有效地克服了TME介导的抑制,并与PD1阻断等现有免疫疗法协同作用.
- 这些发现对开发下一代向性癌症疗法,特别是针对HCC产生影响.
更多相关视频
相关概念视频
Tumor Immunotherapy
514
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
514
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


